-
EZ Cap™ Reagent GG: p21 mRNA Evidence
2026-09-19
EZ Cap™ Reagent GG is identified as product SKU B8177, but the supplied record does not define its cap chemistry or performance specifications. The referenced 2026 FASEB Journal study supports intravesical p21 mRNA–loaded lipid nanoparticles as a localized bladder-cancer research strategy, not as validation of this reagent.
-
Tetramethylrhodamine ethyl ester perchlorate: TMRE Workflow
2026-09-18
Use Tetramethylrhodamine ethyl ester perchlorate (TMRE) to convert mitochondrial membrane-potential changes into live-cell imaging and flow-cytometry data. This workflow shows how to distinguish depolarization from ROS accumulation and connect mitochondrial injury to caspase-3, NDUFS1, and ERO1α mechanisms.
-
EZ Cap™ Reagent GG in p21 mRNA-LNP Design
2026-09-18
Discover how EZ Cap™ Reagent GG can be evaluated as an upstream variable in p21 mRNA-LNP development for localized bladder cancer therapy. This article connects 5′-cap quality with translation, innate immune control, formulation performance, and assay design.
-
Mildronate Lipidoids for Lower-Inflammation mRNA Delivery
2026-09-17
The 2024 ACS Nano study developed mildronate-derived cationic lipids for low-dose lipid nanoparticles that preserved effective mRNA delivery while reducing local inflammation relative to an SM102-based comparator. In prophylactic and therapeutic B16OVA melanoma models, the mLNP-69 formulation supported cancer vaccine delivery, tumor prevention, or delayed tumor progression.
-
Firefly Luciferase mRNA: Workflow & Optimization
2026-09-17
Firefly Luciferase mRNA (ARCA, 5-moUTP) provides a sensitive, transient readout for delivery, expression, viability, and imaging studies. This workflow-focused guide shows how to handle the transcript, design controls, evaluate freeze–thaw effects in lipid nanoparticles, and troubleshoot weak or variable bioluminescence.
-
Epalrestat and Polyol Flux in Cancer Research
2026-09-16
Epalrestat is an aldose reductase inhibitor that enables a more precise way to study polyol-pathway flux, fructose metabolism, and oxidative stress. This article presents an assay-centered framework that separates metabolic mechanism from downstream cancer phenotypes while defining translational limits.
-
Reporter mRNA as a Translation Strategy
2026-09-16
A mechanistic and strategic guide to using firefly luciferase mRNA as a benchmark for translation, delivery, biodistribution, and translational decision-making.
-
Sodium dicloxacillin monohydrate: Assay Guide
2026-09-15
This scenario-driven guide explains how Sodium dicloxacillin monohydrate, SKU C8716, can support controlled Gram-positive infection and cell-viability workflows without confusing antibacterial activity with direct mammalian cytotoxicity. It combines product benchmarks, pH-aware experimental design, analytical-method cautions, and practical vendor-selection criteria.
-
nor-Binaltorphimine dihydrochloride in KOR Assays
2026-09-15
Use nor-Binaltorphimine dihydrochloride to test whether κ-opioid receptor signaling is necessary for opioid-driven changes in cellular, spinal, or behavioral readouts. This guide connects a recent brain-to-spinal pain study with practical antagonist assay design, formulation controls, and troubleshooting strategies.
-
Talin1–Piezo1–YAP Axis in Atherosclerosis
2026-09-14
A 2026 study identifies Talin1 as a mechanistic regulator linking Piezo1-mediated calcium influx to YAP-dependent endothelial inflammation. Using atherosclerotic mice and disturbed-flow endothelial models, the work positions Talin1 as a potential target for dissecting vascular inflammation rather than merely a plaque-associated marker.
-
JC-1 Mitochondrial Membrane Potential Assay Guide
2026-09-14
Explore how the JC-1 Mitochondrial Membrane Potential Assay Kit converts mitochondrial polarization into a ratiometric readout for apoptosis assay design and mitochondrial function analysis. This guide connects ΔΨm measurement with mechanistic insights from recent gold(I)-based cancer immunomodulation research while defining the assay’s practical limits.
-
ARCA EGFP mRNA as an LNP Decision Tool
2026-09-13
ARCA EGFP mRNA can function as more than a fluorescent control: it is a practical diagnostic for separating delivery, intracellular release, and translation in mammalian cells. This article connects reporter design with lipid nanoparticle assay decisions and interprets findings from a macrophage-delivery study.
-
Epalrestat: A Metabolic Lens for Cancer Assays
2026-09-12
Epalrestat is an aldose reductase inhibitor that can help researchers distinguish endogenous polyol-pathway fructose production from imported fructose in cancer metabolism assays. This article presents a mechanistic, control-driven framework linking metabolic flux, oxidative stress, and pathway interpretation.
-
C34 TLR4 Inhibitor: From Signal to Assay
2026-09-11
C34 is a selective TLR4 inhibitor for testing LPS-driven inflammatory signaling in macrophages, enterocytes, and related models. This article develops a cross-model framework that uses C34 to distinguish pathway causality from correlation, including insights from recent Taxus chinensis neuroinflammation research.
-
2-APB Workflow for ER Calcium Signaling
2026-09-11
2-APB enables practical dissection of IP3R-mediated calcium release, store-operated calcium entry, and downstream autophagy–apoptosis decisions. This workflow connects live Ca2+ imaging with calpain, LC3-II, ATG5, and caspase-3 readouts while addressing the compound’s concentration-dependent selectivity limits.